Key autophagic targets and relevant small-molecule compounds in cancer therapy

Area of Science:

• Cell Biology
• Oncology
• Pharmacology

Background:

• Autophagy is a fundamental cellular process involving lysosomal degradation of damaged organelles and proteins, essential for cell survival and homeostasis.
• Autophagy's role in cancer is complex, exhibiting dual functions that can either promote tumor progression or trigger cancer cell death.
• Understanding autophagy's intricate mechanisms is critical for developing novel cancer therapeutic strategies.

Purpose of the Study:

• To review the multifaceted roles of autophagy in cancer development and progression.
• To identify key autophagy-related molecular targets and signaling pathways implicated in oncogenesis.
• To explore the potential of small-molecule drugs in modulating autophagy for cancer treatment.

Main Methods:

• Literature review of studies investigating autophagy in various cancer types.
• Analysis of signaling pathways, including PI3K/AKT/mTORC1 and p53, that regulate autophagy.
• Compilation of data on small-molecule compounds that modulate autophagic activity.

Main Results:

• Autophagy can support cancer cell survival by providing metabolic support or induce cell death through mechanisms like increased genetic instability.
• Key molecular players such as mTORC1, PI3K, AKT, Beclin-1, and p53 are crucial regulators of autophagy in cancer.
• Several small-molecule drugs, including rapamycin derivatives, PP242, AZD8055, spautin-1, tamoxifen, oridonin, and metformin, demonstrate the ability to modulate autophagy in cancer.

Conclusions:

• Autophagy's dual role in cancer necessitates careful consideration for therapeutic targeting.
• Targeting specific autophagy-related elements presents a promising strategy for small-molecule drug development in oncology.
• Modulating autophagic pathways with small compounds offers a potential future approach to combat cancer effectively.